Diabetic Retinopathy Market Size, Share and Growth Outlook, 2026

Diabetic Retinopathy Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Diabetic Retinopathy Market size is forecast to increase from $10.86 Billion in 2026 to $18.11 Billion in 2034 at a CAGR of 6.6% between 2026 and 2034.

The Diabetic Retinopathy market report provides detailed analysis and outlook of Diabetic Retinopathy segments including By Disease Type (Non-Proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy ), By Management (Anti-VEGF Injections, Intraocular Steroid, Laser Photocoagulation Surgery, Vitrectomy Procedures), By Patient Age Demographics (Under 40 Years, 40 to 64 Years, 65 Years and Above), By End-User Facility (General Hospitals and Multi-Specialty Clinics, Specialized Ophthalmology Centers and Retinal Clinics, Ambulatory Surgical Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Diabetic Retinopathy Industry Overview

The diabetic retinopathy industry is undergoing substantial transformation as advances in biologic therapies, artificial intelligence-assisted imaging, predictive analytics, and novel pharmaceutical approaches reshape the management of diabetes-related retinal disease. Diabetic retinopathy remains one of the leading causes of preventable vision loss globally, affecting millions of individuals with diabetes and creating significant clinical and economic burdens for healthcare systems. The industry is increasingly focused on preserving vision, preventing disease progression, reducing treatment-related complications, and improving long-term patient outcomes through precision diagnostics and targeted therapeutics. Emerging innovations in anti-vascular endothelial growth factor (anti-VEGF) therapies, advanced retinal imaging technologies, machine learning-based disease prediction, and non-invasive treatment alternatives are redefining standards of care across both non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR).

Anti-VEGF Biologics Reshaping Proliferative Diabetic Retinopathy Treatment

A major trend within the diabetic retinopathy market is the growing preference for targeted biologic therapies over traditional destructive laser procedures. Primary clinical outcomes from the Phase 3 CONDOR clinical trial demonstrated that intravitreal brolucizumab significantly outperformed conventional panretinal photocoagulation (PRP) laser therapy in patients with proliferative diabetic retinopathy. The findings showed superior long-term vision preservation while reducing the risk of visual field contraction, a common limitation associated with laser-based interventions.
The results highlight the increasing role of anti-VEGF biologics in diabetic retinopathy treatment by offering a less destructive therapeutic approach that effectively controls retinal neovascularization while maintaining stable intraocular safety profiles. As clinicians seek therapies that preserve retinal function and optimize visual outcomes, biologic retinal treatments are becoming increasingly central to diabetic retinopathy management. Growing adoption of anti-VEGF therapies, retinal vascular disease treatments, intravitreal biologics, and advanced diabetic eye disease therapeutics continues to drive innovation across the diabetic retinopathy industry.

Artificial Intelligence and Predictive Imaging Advancing Disease Monitoring

The diabetic retinopathy industry is also experiencing rapid advancement in predictive diagnostics and imaging technologies. A post-hoc multicenter analysis utilizing data from the Diabetic Retinopathy Clinical Research Network (DRCR Retina Network) validated the effectiveness of machine learning-assisted Ultra-Widefield Fluorescein Angiography (UWF-FA) for long-term disease risk assessment. The analysis demonstrated that a 1% or greater increase in the automated panretinal leakage index at one year was strongly associated with a significantly elevated hazard ratio for severe non-proliferative diabetic retinopathy progression, vitreous hemorrhage, and secondary macular complications over a four-year period.
These findings underscore the growing importance of artificial intelligence in diabetic retinopathy screening, monitoring, and prognostic evaluation. Machine learning algorithms integrated with advanced retinal imaging platforms enable clinicians to identify high-risk patients earlier and implement more personalized treatment strategies. The increasing use of AI-powered retinal imaging, predictive ophthalmology analytics, ultra-widefield angiography systems, diabetic retinopathy risk stratification tools, and automated disease monitoring technologies is strengthening precision medicine approaches within diabetic eye care.

Oral Therapeutics Creating New Opportunities in Diabetic Retinopathy Management

Another significant trend shaping the diabetic retinopathy market is the development of non-invasive pharmaceutical therapies designed to reduce reliance on chronic intraocular injections. International clinical trial registries have documented active enrollment and dosing activities for VX-01, an investigational oral therapy currently being evaluated in a Phase 2 randomized, placebo-controlled clinical study. The treatment is being developed specifically for adults with moderate-to-severe non-proliferative diabetic retinopathy.
Unlike conventional retinal therapies that require repeated intravitreal administration, VX-01 is designed as a daily oral tablet targeting systemic metabolic pathways involved in ocular inflammation and microvascular dysfunction. By addressing underlying disease mechanisms through systemic intervention, the therapy aims to slow retinal degeneration and reduce progression toward advanced diabetic retinopathy stages. The emergence of oral diabetic retinopathy treatments, inflammation-targeted retinal therapeutics, non-invasive ophthalmology drugs, and next-generation diabetic eye disease therapies reflects the industry's broader commitment to expanding treatment options and improving patient convenience.
As biologic therapies, AI-assisted retinal diagnostics, predictive imaging platforms, and oral treatment candidates continue to advance, the diabetic retinopathy industry is moving toward a more personalized, technology-driven, and patient-centered model of vision preservation and retinal disease management.

Diabetic Retinopathy Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Diabetic Retinopathy market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd (Genentech), Bayer AG, Novartis AG, AbbVie Inc. (Allergan), Alimera Sciences, Inc., Bausch + Lomb Corporation, Oxurion NV, Kodiak Sciences Inc., Carl Zeiss Meditec AG. The Diabetic Retinopathy market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Diabetic Retinopathy industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Diabetic Retinopathy Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Diabetic Retinopathy companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Diabetic Retinopathy markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Diabetic Retinopathy Market Competitive Benchmarking and Company Analysis

Leading companies in Diabetic Retinopathy industry include- Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd (Genentech), Bayer AG, Novartis AG, AbbVie Inc. (Allergan), Alimera Sciences, Inc., Bausch + Lomb Corporation, Oxurion NV, Kodiak Sciences Inc., Carl Zeiss Meditec AG. The Diabetic Retinopathy market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Diabetic Retinopathy Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Diabetic Retinopathy market remains one of the strongest-performing segments in the country.
The US Diabetic Retinopathy Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Diabetic Retinopathy market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Diabetic Retinopathy industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Diabetic Retinopathy markets

Canada's strong Diabetic Retinopathy sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Diabetic Retinopathy market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Diabetic Retinopathy Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Diabetic Retinopathy market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Diabetic Retinopathy population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Diabetic Retinopathy industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Diabetic Retinopathy market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Diabetic Retinopathy sales through 2034

France Diabetic Retinopathy companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Diabetic Retinopathy Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Diabetic Retinopathy distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Diabetic Retinopathy Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Diabetic Retinopathy market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Diabetic Retinopathy industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Diabetic Retinopathy industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Diabetic Retinopathy Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Diabetic Retinopathy market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Diabetic Retinopathy market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Diabetic Retinopathy Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Diabetic Retinopathy Market Segmentation

By Disease Type
Non-Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
By Management
Anti-VEGF Injections
Intraocular Steroid
Laser Photocoagulation Surgery
Vitrectomy Procedures
By Patient Age Demographics
Under 40 Years
40 to 64 Years
65 Years and Above
By End-User Facility
General Hospitals and Multi-Specialty Clinics
Specialized Ophthalmology Centers and Retinal Clinics
Ambulatory Surgical Centers

Top Companies in Diabetic Retinopathy Industry

Regeneron Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd (Genentech)
Bayer AG
Novartis AG
AbbVie Inc. (Allergan)
Alimera Sciences, Inc.
Bausch + Lomb Corporation
Oxurion NV
Kodiak Sciences Inc.
Carl Zeiss Meditec AG

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025